2002
DOI: 10.1046/j.1468-3083.2002.00559_10.x
|View full text |Cite
|
Sign up to set email alerts
|

Annular leucocytoclastic vasculitis: response to dapsone

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
12
0
2

Year Published

2004
2004
2021
2021

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 22 publications
(16 citation statements)
references
References 8 publications
2
12
0
2
Order By: Relevance
“…Tamoxifen [24], anastrozole [25], etoposide [26], erlotinib [27], and capecitabine [28] are agents that have been implicated in the literature. Again, subclinical infections suffered by these patients based on immunosuppression may also cause vasculitis [29, 30].…”
Section: Discussionmentioning
confidence: 99%
“…Tamoxifen [24], anastrozole [25], etoposide [26], erlotinib [27], and capecitabine [28] are agents that have been implicated in the literature. Again, subclinical infections suffered by these patients based on immunosuppression may also cause vasculitis [29, 30].…”
Section: Discussionmentioning
confidence: 99%
“…Dapsone is primarily an anti‐inflammatory medication with a predominantly antineutrophilic effect that is frequently used in various vasculitic diseases and neutrophilic dermatoses, such as Sweet's syndrome (SS), erythema elevatum diutinum (EED), pyoderma gangrenosum (PG), dermatitis herpetiformis (DH), and HSP 34 . A few cases have shown complete resolution in cutaneous LCV and refractory HUV with doses of 100–200 mg daily 35–37 . Although directly reported cases are few in the literature, dapsone is considered a frequent treatment modality in many vasculitis reviews 6,7,11 .…”
Section: Treatmentmentioning
confidence: 99%
“…In our case, only the combination of lamivudine to treat the hepatitis and dapsone 200 mg/day successfully ameliorated the clinical occurrence of the annular leucocytoclastic vasculitis and provoked a long‐lasting remission 8 …”
mentioning
confidence: 62%